Shopping Cart
- Remove All
- Your shopping cart is currently empty
ARD-266 is a PROTAC degrader based on the von Hippel-Lindau E3 ligase, inducing the degradation of AR proteins, and can be used in prostate cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $696 | In Stock | |
5 mg | $1,530 | In Stock | |
10 mg | $2,480 | In Stock | |
25 mg | $3,690 | In Stock | |
50 mg | $4,980 | In Stock |
Description | ARD-266 is a PROTAC degrader based on the von Hippel-Lindau E3 ligase, inducing the degradation of AR proteins, and can be used in prostate cancer research. |
In vitro | ARD-266 (100 nM; 1-24 hours; LNCaP and VCaP cells) treatment effectively reduces the AR protein level within 3 h and achieves near-complete AR elimination with a 6 h treatment in the LNCaP cells. ARD-266 (1-10000 nM; 24 hours; LNCaP cells) treatment effectively suppresses the expression of PSA, TMPRSS2, and FKBP5 genes in a dose-dependent manner and is capable of reducing the mRNA levels of PSA, TMPRSS2, and FKBP5 genes by >50% at 10 nM in the LNCaP cell line.[1] |
Alias | ARD266 |
Molecular Weight | 915.51 |
Formula | C52H59ClN6O7 |
Cas No. | 2666951-70-6 |
Smiles | O([C@@H]1C(C)(C)[C@@H](NC(=O)C2=CC=C(C#CC3CCN(C(C[C@H](NC(=O)[C@H]4N(C([C@H]([C@H](C)C)C=5ON=C(C)C5)=O)C[C@H](O)C4)C6=CC=CC=C6)=O)CC3)C=C2)C1(C)C)C7=CC(Cl)=C(C#N)C=C7 |
Relative Density. | no data available |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (87.38 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.